At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Escalation and Dose Expansion Study of WJ01024 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy for Patients With Advanced Cancer
In Brief
A Phase 1 clinical trial evaluating WJ01024 for Advanced Hematologic Malignancies and Advanced Solid Tumors. Terminated early, enrolled 23 participants across 4 sites.
Signals
Detailed Summary
A clinical study of WJ01024 in subjects with advanced cancer in China, to evaluate the safety, tolerability, PK and efficacy of WJ01024. This study includes a dose escalation part and a dose expansion part. Patients receive WJ01024 on Day 1 and Day 3 of each week, 4 weeks as a cycle, until disease progression, or intolerable toxicity , withdrawal of consent, or end of the study, whichever occurs first.
Study Details
Timeline
Interventions
5mg QD: WJ01024, Q4W, once per day
5mg BID: WJ01024, Q4W, twice per day
10mg BID: WJ01024, Q4W, twice per day
40mg BIW: WJ01024, Q4W, twice per week
60mg BIW: WJ01024, Q4W, twice per week
80mg BIW: WJ01024, Q4W, twice per week
60mg QW: WJ01024, Q4W, once per week
80mg QW: WJ01024, Q4W, once per week
50mg QW: WJ01024, Q4W, once per week
40mg QW: WJ01024, Q4W, once per week